Sana Biotechnology Q2 2026 Earnings Results & Report

Sana Biotechnology EPS Results

• Actual EPS: -$0.13
• Consensus EPS: -$0.1469
• Beat/Miss: Beat by +$0.0169
• One Year Ago EPS: N/A
• EPS Beat Rate: 7 of last 8 quarters

Sana Biotechnology Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Sana Biotechnology (NASDAQ:SANA) is a biotechnology company focused on developing engineered cell and gene therapies intended to treat diseases with significant unmet medical needs. The company’s approach is designed to enable the delivery of functional cells or genetic material to patients while addressing challenges such as immune rejection, manufacturing complexity and the need for repeated treatment.

Sana’s research programs include both ex vivo therapies, in which cells are modified outside the body before being administered to a patient, and in vivo therapies, which are designed to modify or deliver therapeutic material directly within the body. Its pipeline has included engineered immune-cell therapies, including investigational CAR T-cell programs, as well as cell-replacement approaches for conditions such as diabetes and other serious diseases.

Founded in 2018 and headquartered in Seattle, Washington, Sana has focused primarily on research and development rather than commercialized products. The company became publicly traded on the Nasdaq under the symbol SANA in 2021. Sana’s operations and clinical development activities are centered in the United States, with its programs subject to regulatory and clinical evaluation. Steve Harr, a co-founder of the company, has served as its chief executive officer.